Individuals with personal or first-degree family history of autoimmune diseases or B-cell neoplasms
Care Setting
Population-based genetic and epidemiological risk assessment; clinical oncology and immunology
Key Highlights
Personal history of autoimmune diseases is a known risk factor for mature B-cell neoplasms.
Family history of certain autoimmune diseases is associated with increased or decreased risks of specific B-cell neoplasms.
Pleiotropy may explain shared genetic susceptibility between autoimmune diseases and B-cell neoplasms, with possible opposite allelic effects.
Guideline-Based Recommendations
Diagnosis
Consider family history of autoimmune diseases when assessing risk for B-cell neoplasms.
Use nationwide medical records and registries for comprehensive family and personal disease history.
Apply standardized incidence ratios (SIRs) adjusted for age, gender, socioeconomic status, and residential area in risk evaluation.
Management
Monitor individuals with family history of specific autoimmune diseases (e.g., angiitis hypersensitive, Sjogren syndrome) for increased risk of NHL.
Recognize decreased risk associations (e.g., HL with ankylosing spondylitis) in risk stratification.
No significant familial risk associations identified for multiple myeloma; management should consider personal risk factors.
Monitoring & Follow-up
Surveillance for B-cell neoplasms in patients with autoimmune diseases and their first-degree relatives.
Monitor autoimmune disease development in families with B-cell neoplasms, noting increased risks for certain AIDs (e.g., rheumatoid arthritis, Wegener granulomatosis).
Adjust monitoring strategies based on specific autoimmune disease and neoplasm risk patterns.
Risks
Increased familial risk of NHL with autoimmune diseases such as angiitis hypersensitive, Guillain-Barre syndrome, discoid lupus erythematosus, Sjogren syndrome, and psoriasis.
Increased familial risk of HL with pemphigus; decreased risk with glomerular nephritis acute, ankylosing spondylitis, and Graves disease.
No significant familial risk associations for multiple myeloma with autoimmune diseases.
Patient & Prescribing Data
Patients with personal or family history of autoimmune diseases or B-cell neoplasms
No direct treatment data provided; genetic and familial risk information may guide personalized surveillance and early intervention strategies.
Clinical Best Practices
Incorporate detailed family history of autoimmune diseases in clinical risk assessment for B-cell neoplasms.
Use population-based registries and standardized diagnostic coding for accurate epidemiological evaluation.
Recognize heterogeneity in autoimmune diseases and their differential associations with lymphoma subtypes.
Consider genetic pleiotropy and possible opposite allelic effects when interpreting familial risk data.
Apply age, gender, and socioeconomic adjustments in risk calculations to improve accuracy.
